Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
Clinical trial NCT02961218 · COMPLETED
Trial details
- NCT number
- NCT02961218
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-05
- Primary completion
- 2019-06-27
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.